How WILSERDLY is Designed to Work Fact Sheet

WILSERDLY™ (giredestrant) is a prescription medicine used alone to treat adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that is in early stages (stage I, II, III) at intermediate to high risk of cancer coming back.

Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer **is the most common form of breast cancer**, accounting for roughly

70% of all cases.[1]



Approximately

225,000 U.S. women

will be diagnosed with HR+, HER2- breast cancer this year.[1,2]

What is ER+ breast cancer?

Estrogen receptor-positive (ER+) breast cancer is the most common subtype of HR+ breast cancer.[3]



It means the cancer cells have sensors (called estrogen receptors) that the hormone estrogen attaches to, sending signals for the cancer cells to grow.[3]



Think of estrogen as the fuel and the estrogen receptors on the cancer cells as the engines. When estrogen binds to the estrogen receptor, it fuels the engine that causes the cancer cell to grow and divide.[3]

What is hormone therapy for ER+ breast cancer?

Treatment for ER+ breast cancer is designed to slow or stop cancer growth by targeting either the hormones that fuel it or the hormone receptors.[4] Hormone therapy (also called endocrine therapy) is a type of treatment for ER+ breast cancer that:[5]



Lowers estrogen levels in the body

OR



Disrupts the cancer's ability to use estrogen for growth by targeting the estrogen receptor

The specific treatment plan may vary depending on the stage of the cancer, whether it has spread, and how the cancer responds over time.[5,6]

What is WILSERDLY™ (giredestrant) and how is it designed to work?

WILSERDLY is an oral selective estrogen receptor degrader (SERD), which means it is a pill that is designed to work in ER+, HER2- early breast cancer two ways.[7]

1. **Block the fuel from getting to the engine:** WILSERDLY targets cancer cells and attaches to estrogen receptors, preventing estrogen—which is the fuel that estrogen receptors need to activate ER+, HER2- breast cancer growth—from attaching to the estrogen receptors.

2. **Break down the engine:** WILSERDLY destroys the estrogen receptors in cancer cells, so that the breast cancer cells can no longer use them to grow and multiply.



This infographic is intended for U.S. consumer media only as background context for news reporting. The information provided is intended for reference purposes only and is not comprehensive of all aspects of breast cancer or available treatment options.

Important Safety Information

What is WILSERDLY™?
WILSERDLY is a prescription medicine used alone to treat adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that is in early stages (stage I, II, III) at intermediate to high risk of cancer coming back.

It is not known if WILSERDLY is safe and effective in children.

What are the possible side effects of WILSERDLY?
WILSERDLY can cause serious side effects, including:

- **Slow heart rate (bradycardia)**. WILSERDLY can cause your heart rate to slow down. Your healthcare provider will monitor your heart rate more frequently if you have a history of a slow heart rate or take certain heart medicines. Tell your healthcare provider if you develop any signs and symptoms of a slow heart rate, including:
  - dizziness
  - lightheadedness
  - fainting
  - shortness of breath
  - chest pain
  - tiredness

The most common side effects and abnormal blood test results of WILSERDLY include:

- muscle and joint pain
- decreased white blood cell counts
- increased liver enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT], and alkaline phosphatase [ALP])
- sudden feelings of heat and sweating (hot flash)
- increased triglycerides and cholesterol blood levels
- tiredness
- decreased red blood cell counts
- increased calcium blood levels
- headache
- decreased calcium blood levels
- increased potassium blood levels
- increased creatinine blood levels (kidney function test)
- nausea
- decreased sodium blood levels
- slow heart rate
- decreased potassium blood levels
- COVID-19

WILSERDLY may affect fertility in males and in females who are able to become pregnant. Talk to your healthcare provider if this is a concern for you.

These are not all the possible side effects of WILSERDLY.

Before taking WILSERDLY, tell your healthcare provider about all of your medical conditions, including if you:

- have a slow heart rate (bradycardia)
- are pregnant or plan to become pregnant. WILSERDLY can harm your unborn baby
- **Females who are able to become pregnant:**
  - Your healthcare provider will do a pregnancy test before you start treatment with WILSERDLY.
  - Use effective non-hormonal birth control (contraception) during treatment with WILSERDLY, and for 2 weeks after the last dose of WILSERDLY. Talk to your healthcare provider about birth control methods that may be right for you.
  - Tell your healthcare provider right away if you become pregnant during treatment with WILSERDLY or think you may be pregnant.
- **Males with female partners who are able to become pregnant:**
  - Use effective birth control (contraception) during treatment with WILSERDLY, and for 2 weeks after the last dose of WILSERDLY.
- are breastfeeding or plan to breastfeed. It is not known if WILSERDLY passes into your breast milk. **Do not** breastfeed during treatment with WILSERDLY, and for 2 weeks after the last dose of WILSERDLY. Talk to your healthcare provider about the best way to feed your baby during this time.
- have an intolerance to some sugars found in milk and milk products. WILSERDLY capsules contain lactose monohydrate.

Tell your healthcare provider about all the medicines you take, including prescription medicines, and over-the-counter medicines, vitamins, and herbal supplements. Taking WILSERDLY with certain other medicines may affect how WILSERDLY works and may cause side effects. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

What should I avoid while taking WILSERDLY?
Avoid eating grapefruit and drinking grapefruit juice during treatment with WILSERDLY.
Grapefruit may increase the amount of WILSERDLY in your blood.

Talk to your healthcare provider for more information about the benefits and risks of WILSERDLY.

You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555

Please see Important Safety Information as well as the WILSERDLY full Prescribing Information and Patient Information.

References:

1. Cancer stat facts: female breast cancer subtypes. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Accessed November 2026. https://seer.cancer.gov/statfacts/html/breast-subtypes.html
2. ER-positive breast cancer. Cleveland Clinic. Accessed November 2026. https://my.clevelandclinic.org/health/diseases/er-positive-breast-cancer
3. Breast cancer HER2 status. American Cancer Society. Updated January 29, 2025. Accessed November 2026. https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-her2-status.html
4. HER2 negative. NCI Dictionary of Cancer Terms. National Cancer Institute. Accessed November 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/her2-negative
5. A study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of adjuvant endocrine monotherapy in participants with estrogen receptor-positive, HER2-negative early breast cancer (lidERA Breast Cancer). ClinicalTrials.gov identifier: NCT04961996. Updated June 17, 2026. Accessed November 2026. https://clinicaltrials.gov/study/NCT04961996
6. Bardia A, Schmid P, Martin M, et al. Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: results from the global phase 3 lidERA Breast Cancer trial. Presented at: San Antonio Breast Cancer Symposium; December 9-12, 2025; San Antonio, TX. Abstract GS1-10.
7. WILSERDLY. Prescribing information. Genentech, Inc; 2026.

© 2026 Genentech, Inc. All rights reserved.

1 DNA Way, South San Francisco, CA 94080-4990

Genentech
A Member of the Roche Group

MS-US-00034356(v1.0) 11/26